Zoekresultaten - Nigel McCracken

  • Toon 1 - 2 resultaten van 2
Verfijn jouw resultaten
  1. 1
    Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer

    Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer door Sheena Bhalla, Farjana Fattah, Chul Ahn, Jessica N. Williams, Alyssa Macchiaroli, Jonathan Padro, Meredith Pogue, Jonathan E. Dowell, William C. Putnam, Nigel McCracken, David Micklem, Rolf A. Brekken, David E. Gerber

    Gepubliceerd in 2023
    Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:
  2. 2
    Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial

    Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b/2a trial door Sonja Loges, Michael Heuser, Jörg Chromik, Grerk Sutamtewagul, Silke Kapp‐Schwoerer, Monica Crugnola, Nicola Di Renzo, Roberto M. Lemoli, Daniele Mattei, Walter Fiedler, Yesid Alvarado‐Valero, Isabel Ben‐Batalla, Jonas Waizenegger, Lisa-Marie Rieckmann, Melanie Janning, Maike Collienne, Charles D. Imbusch, Niklas Beumer, David Micklem, Linn Nilsson, Noëlly Madeleine, Nigel McCracken, Cristina Oliva, Claudia Gorcea-Carson, Bjørn Tore Gjertsen

    Gepubliceerd in 2025
    Volledige tekst Volledige tekst
    Artigo
    Toevoegen aan favorieten
    Bewaard in:

Zoekinstrumenten: